Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN)
Read time: 1 mins
Last updated:14th Jul 2008
The primary endpoint of the proposed trial is to assess if tamoxifen at a low dose, 5mg/day, reduces the incidence of invasive breast cancer and ductal carcinoma in situ (DIN 1c, 2, 3) of the breast, in women operated on for lobular intraepithelial neoplasia (LIN1, 2 and 3) or ER-positive ductal intraepithelial neoplasia (DIN1b, DIN 2, DIN3, 1a excluded) of the breast.
|Study start date||2008-07-14|